Catalog No.
DHH02202
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q15116
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MK-3475, CAS: 1374853-91-4
Clone ID
Pembrolizumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study., PMID:40449498
Guidelines of Onkopedia: What is new? Esophageal Cancer., PMID:40451170
Pembrolizumab Induced Aortitis in a Patient With Head and neck Cancer: A Case Report., PMID:40454445
Remote Clinical Pharmacist Impact on Reducing Total Cost of Care in Enhancing Oncology Model-Enrolled Oncology Practices., PMID:40454696
Erythema multiforme as a rare skin manifestation during pembrolizumab treatment: a case report and literature review., PMID:40454868
Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy., PMID:40455297
Case Report: Oral lichenoid mucositis in a patient with metastatic renal cell carcinoma undergoing treatment with pembrolizumab and axitinib., PMID:40458718
New Treatment Approaches for Triple-Negative Breast Cancer., PMID:40460322
Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial., PMID:40460988
[Network pharmacology and molecular docking explore mechanism of Croci Stigma in treating immune checkpoint inhibitor-associated myocarditis]., PMID:40461207
Impact of medications on the efficacy of immune checkpoint inhibitors in patients with recurrent or metastatic head and neck cancer., PMID:40465127
Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma., PMID:40465327
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study., PMID:40466642
Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis., PMID:40469302
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial., PMID:40472658
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-PD-(L)1 Plus Platinum Chemotherapy., PMID:40473109
Maintenance with niraparib in patients with stage III, stage IV, chemo-naïve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trial., PMID:40473279
Assessing individual head and neck squamous cell carcinoma patient response to therapy through integration of functional and genomic data., PMID:40473660
Immune checkpoint inhibitor therapy in metastatic renal cell carcinoma: tumour response and immune-related renal vasculitis following cytoreductive nephrectomy., PMID:40474803
Two Cases of Enfortumab Vedotin-Induced Drug Eruption Diagnosed Based on the Distinctive Epidermal Mitotic Figures in Patients Receiving Combination Therapy With Pembrolizumab., PMID:40476598
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of belantamab mafodotin for multiple myeloma, asciminib for leukemia, osimertinib for lung cancer, amivantamab for lung cancer, and pembrolizumab for pleural mesothelioma in Japan., PMID:40481943
Cost-Utility and Budget Impact Analysis of Immunotherapy for First-Line Treatment of Advanced Kidney Cancer in Latin America: Evidence From Uruguay., PMID:40482312
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies., PMID:40486134
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations., PMID:40486486
Cost-effectiveness of chemotherapy in advanced and recurrent endometrial cancer., PMID:40487854
Implementing performance-based risk-sharing agreements in non-small cell lung cancer immunotherapy: a real-world data case study., PMID:40489036
First-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real-World Study., PMID:40491285
Pembrolizumab-induced toxic epidermal necrolysis with limited mucosal involvement., PMID:40491518
Response of EGFR-mutated pulmonary pleomorphic carcinoma to pembrolizumab., PMID:40491684
First-line pembrolizumab used concurrently with multi-agent chemotherapy and inhaled tranexamic acid (TXA) for management of stage III mixed trophoblastic tumor complicated by pulmonary hemorrhage., PMID:40496174
Severe immunotherapy-related thrombocytopenia in metastatic bone cancer: a multicenter retrospective case series highlighting early recognition and management., PMID:40496609
Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy., PMID:40496844
Obesity paradox role in the immunosuppressive treatment of hepatocellular carcinoma., PMID:40497086
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer., PMID:40498298
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas., PMID:40499147
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma., PMID:40501309
Metastatic renal cell carcinoma to the glans penis: A case report of rare presentation., PMID:40502920
Managing severe dermatitis and grade 4 pneumonitis in a patient with non-small-cell lung cancer following pembrolizumab treatment: A case report., PMID:40503034
Adjuvant pembrolizumab following kidney cancer surgery A novel patient decision aid to facilitate shared decision-making., PMID:40503866
Management of Cutaneous Melanoma, With a Special Focus on Desmoplastic Melanoma., PMID:40505073
[Lichen sclerosus induced by pembrolizumab]., PMID:40506272
Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis., PMID:40506696
Skeletal Muscle Density as a Predictive Marker for Pathologic Complete Response in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemoimmunotherapy., PMID:40507249
Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations., PMID:40507271
Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data., PMID:40507314
Impaired Overall Survival of Melanoma Patients Due to Antibiotic Use Prior to Immune Checkpoint Inhibitor Therapy: Systematic Review and Meta-Analysis., PMID:40507352
Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update., PMID:40507360
Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report., PMID:40510022
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC., PMID:40511820
Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis., PMID:40512324
For research use only. Not for human or drug use.
